Farjah Farhood, Backhus Leah M, Varghese Thomas K, Manning James P, Cheng Aaron M, Mulligan Michael S, Wood Douglas E
1 Division of Cardiothoracic Surgery, 2 Surgical Outcomes Research Center, University of Washington, Seattle, USA.
J Thorac Dis. 2015 Apr;7(4):576-84. doi: 10.3978/j.issn.2072-1439.2015.02.09.
A prediction model for pathologic N2 (pN2) among lung cancer patients with a negative mediastinum by positron emission tomography (PET) was recently internally validated. Our study sought to determine the external validity of that model.
A cohort study [2005-2013] was performed of lung cancer patients with a negative mediastinum by PET. Previously published model coefficients were used to estimate the probability of pN2 based on tumor location and size, nodal enlargement by computed tomography (CT), maximum standardized uptake value (SUVmax) of the primary tumor, N1 disease by PET, and pretreatment histology.
Among 239 patients, 18 had pN2 [7.5%, 95% confidence interval (CI): 4.5-12%]. Model discrimination was excellent (c-statistic 0.80, 95% CI: 0.75-0.85) and the model fit the data well (P=0.191). The accuracy of the model was as follows: sensitivity 100%, 95% CI: 81-100%; specificity 49%, 95% CI: 42-56%; positive predictive value (PPV) 14%, 95% CI: 8-21%, and negative predictive value (NPV) 100%, 95% CI: 97-100%. CI inspection revealed a significantly higher c-statistic in this external validation cohort compared to the internal validation cohort. The model's apparently poor specificity for patient selection is in fact significantly better than usual care (i.e., aggressive but allowable guideline concordant staging) and minimum guideline mandated selection criteria for invasive staging.
A prediction model for pN2 is externally valid. The high NPV of this model may allow pulmonologists and thoracic surgeons to more comfortably minimize the number of invasive procedures performed among patients with a negative mediastinum by PET.
最近对通过正电子发射断层扫描(PET)显示纵隔阴性的肺癌患者的病理N2(pN2)预测模型进行了内部验证。我们的研究旨在确定该模型的外部有效性。
对通过PET显示纵隔阴性的肺癌患者进行了一项队列研究[2005 - 2013年]。根据先前发表的模型系数,基于肿瘤位置和大小、计算机断层扫描(CT)显示的淋巴结肿大、原发肿瘤的最大标准化摄取值(SUVmax)、PET显示的N1疾病以及治疗前组织学来估计pN2的概率。
在239例患者中,18例有pN2[7.5%,95%置信区间(CI):4.5 - 12%]。模型区分度良好(c统计量0.80,95% CI:0.75 - 0.85),且模型与数据拟合良好(P = 0.191)。模型的准确性如下:敏感性100%,95% CI:81 - 100%;特异性49%,95% CI:42 - 56%;阳性预测值(PPV)14%,95% CI:8 - 21%,阴性预测值(NPV)100%,95% CI:97 - 100%。CI检验显示,与内部验证队列相比,该外部验证队列中的c统计量显著更高。该模型在患者选择方面明显较差的特异性实际上显著优于常规治疗(即积极但符合指南的分期)以及侵入性分期的最低指南规定选择标准。
pN2预测模型具有外部有效性。该模型的高NPV可能使肺科医生和胸外科医生能够更放心地尽量减少对PET显示纵隔阴性的患者进行的侵入性操作数量。